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856-3 The Short- and Intermediate-Term Results of 
Mechanical Circulatory Support in Non-transplant 
Candidates
Joseph G. Rogers, Michael K. Pasque, on behalf of the Novacor Investigators, 
Washington University School of Medicine, St. Louis, MO
Background: The use of left ventricular assist devices (LVAD) to support non-transplant
candidates is controversial. We reviewed a large bridge-to-transplant database and found
patients (pts) who were poor transplant candidates by virtue of advanced age or signifi-
cant end-organ dysfunction. The goal of this analysis was to assess the efficacy of LVAD
support in this population.
Methods: We retrospectively reviewed the clinical data of the 225 pts enrolled in a US
bridge-to-transplant trial. All patients had evidence of cardiogenic shock and high cardiac
filling pressures despite optimal medical therapy. High-dose inotropic medications and
intraaortic balloon counterpulsation also satisfied inclusion criteria. Low-risk recipients
(LRR; n=146) were < 65 years of age and had a BUN < 100 mg/dl, Cr <2.5 mg/dl, biliru-
bin < 5.0 mg/dl, negative blood cultures and a pulmonary vascular resistance < 480 dyne
sec/cm5. High-risk recipients (HRR; n=44) had at least one value discordant with those
listed above. A control group (Co; n=35) was identified that met LVAD criteria but did not
receive a device as a result of pt preference, device unavailability, or a mechanical aortic
valve. Intergroup comparisons were analyzed using a student's t-test with p<0.05 consid-
ered significant. Kaplan-Meier analysis was used to estimate survival using log-rank test
to assess significance.
Results: Compared to LRR, the HRR had a lower mean blood pressure (63.9 vs 69.2,
p<0.02), a higher pulmonary vascular resistance (282 vs 219, p=0.01), a higher BUN and
Cr (52 vs 31, p <0.05; 2.3 vs 1.3, p=0.003), and a higher bilirubin (2.2 vs 1.5, p=0.003).
The median survival was 11 days in Co vs 197 days in HRR vs 467 in LRR. The HRR
survival at 30-, 60-, and 90-days was lower than LRR (77%, 72%, 68% vs 89%, 83%,
80%; p=0.02). The median survival of both LVAD groups was statistically superior to Co
(p<0.0001).
Conclusions: 1) Nearly 25% of the bridge-to-transplant LVAD implantation occurs in
HRR who are poor transplant candidates. 2) The early post-implant mortality is predict-
ably higher in HRR 3). Regardless of age and comorbidities, LVAD treated pts had supe-
rior survival compared to those managed with optimal medical therapy.
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856-4 Randomized Comparison of Intra-Aortic Balloon 
Support Versus a Percutaneous Left Ventricular Assist 
Device in Patients With Acute Myocardial Infarction 
Complicated by Cardiogenic Shock
Holger Thiele, Enno Boudriot, Peter Sick, Josef Niebauer, Klaus-Werner Diederich, 
Rainer Hambrecht, Gerhard Schuler, University of Leipzig - Heart Center, Leipzig, 
Germany
Background Mortality in cardiogenic shock (CS)following acute myocardial infarction
(AMI) remains at an unacceptable level despite PCI and use of intraaortic balloon coun-
terpulsation. Frequently patients succumb to low output before the myocardium is able to
recover from the ischemic event. A newly developed percutaneous left ventricular assist
device (VAD) (Tandem Heart™ , Cardiac Assist Inc., Pittsburgh, PA, USA) with active cir-
culatory support might decrease mortality.
Methods and results Since 08/2000 patients in CS after an AMI with revascularization
of the infarct related artery were randomized to either IABP (n=20) or percutaneous VAD
support (n=19). Predicted mortality probability was similar in both groups (71% vs. 75%,
p=n.s.). By VAD support hemodynamic and metabolic parameters could be reversed
more effectively in comparison to IABP treatment (Table, * denotes p<0.05). However,
complications as bleeding requiring transfusion of blood components (n=16 vs. n=8,
p=0.005), limb ischemia (n=6 vs. n=0, p=0.007), or elevated temperature >38.5°C (n=16
vs. n=10, p=0.04) were encountered more frequently after VAD support. 30-day-mortality
was similar (IABP 45% vs. VAD 39%, log-rank, p=0.70).
Conclusions By a newly developed VAD hemodynamic and metabolic parameters can
be reversed more effectively as by standard treatment. However, so far there is no mor-
tality benefit, which may be accounted to more complications by the highly invasive pro-
cedure and the extracorporeal support.
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859-1 High False Positive Rates for Serum B-Type Natriuretic 
Peptide Testing in the Routine Clinical Setting
Mohammad Z. Nawaz, Melissa Ecker, Maryl R. Johnson, Theresa P. Darcy, Nancy K. 
Sweitzer, University of Wisconsin, Madison, WI
Serum BNP measurement may improve heart failure (HF) diagnosis, but results with rou-
tine use might differ from those obtained in clinical trial settings. We assessed perfor-
mance of serum BNP testing for diagnosing HF in a busy tertiary care hospital. Methods:
253 sequential patients (pts) who had serum BNP testing (Triage) ordered in an acute
setting for symptoms of dyspnea or leg swelling from 8/02 - 2/03 were analyzed. Record
review determined presenting symptoms, reason for test, and clinical assessment. Pres-
ence or absence of HF was judged by review of echos for LV dysfunction and/or
increased filling pressures. When there was no echo, review by two cardiologists deter-
mined if HF was present. Results: We found similar sensitivity but markedly lower speci-
ficity of diagnostic BNP testing than published trials (see Table). Of the 77 pts without HF,
43 had BNP levels > 100, and 23 had BNP > 200 pg/ml. These patients were elderly,
78% had a pulmonary process, and 82% had infection and sepsis. 82% had evidence of
pulmonary hypertension. Conclusion: Serum BNP testing has an increased false posi-
tive rate outside the clinical trial setting and may lead to unnecessary and costly cardiac
testing. BNP testing has not been studied in patients with edema, however this was a
common presentation in our population. The recommended cutoff of 100 may be too low
for routine use.
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859-2 Utility of B-Natriuretic Peptide Levels in Predicting 
Outcome of Hospitalized Patients With Congestive 
Heart Failure: Results of the Breathing Not Properly 
(BNP) Multinational Study
Alan S. Maisel, Meenakshi A. Bhalla, Nancy Gardetto, James McCord, Richard M. 
Nowak, Judd E. Hollander, Alan H.B. Wu, Philippe Duc, Torbj ørn Omland, Alan B. 
Storrow, Padma Krishnaswamy, William T. Abraham, Paul Clopton, Gabriel Steg, Marie 
Claude Aumont, Arne Westheim, Cathrine Wold Knudsen, Alberto Perez, Richard Kamin, 
Radmila Kazanegra, Howard C. Herrmann, Peter A. McCullough, The BNP Multinational 
Study Investigators, Veteran's Affairs Medical Center, San Diego, CA, University of 
California, San Diego, CA
OBJECTIVES: We aimed to evaluate the value of BNP levels in predicting subsequent
events (readmission & death) in patients admitted with decompensated heart failure
(CHF). BACKGROUND: Heart failure is the leading cause of hospital admission among
patients over the age of 65 years. Since the BNP levels are increased in ventricular wall
stress, we hypothesized that BNP might be useful in assessing outcomes in patients
admitted with CHF. METHODS: The BNP Multinational Study was a 7 center, prospective
study of 1586 patients who presented with acute dyspnea and had BNP measured upon
arrival. A subset of 452 patients with a final adjudicated diagnosis of CHF who underwent
echocardiography within 30 days of their visit to the ED were evaluated. We followed 227
patients admitted with CHF. BNP levels were measured at admission and discharge &
determined their subsequent adverse events in relation to BNP.RESULT: Of the 227
patients admitted with CHF, 51 events occurred (death: n=9,readmissions: n=
31,unknown cause of death: n=14). The median BNP levels, in patient group with no
adverse events during the follow-up period, at admission and discharge was 653 & 450
(pg/ml) respectively in comparison to 961 & 678 (pg/ml) in patient group with adverse
events. BNP levels were significantly lower both at the time of admission (p=. 048) and at
the time of discharge (p=0.016) in no-adverse event group. The patients in whom BNP
decreased during their hospital stay had less adverse events (21.7%)when compared to
patients in which the BNP increased (33.3%) (P=0.06). The Receiver Operating Charac-
teristic Curve values for BNP at admission and discharge in predicting events was 0.590
(p=0.035) and 0.609 (p=0.014) respectively, whereas the values for creatinine (0.608)
and BUN (0.545) were significant. Also the patients, who had adverse event in the follow-
up after discharge, were found to have significantly longer stay in the hospital at the time
of enrollment (median: 8 days vs. 5 days p=0.018). CONCLUSION: Monitoring BNP lev-
els during hospitalization should help risk stratify patients and likely improve ultimate out-
comes.
IABP Pre IABP Post VAD Pre VAD Post
Cardiac Index (l/min/m2) 1.8± 0.7 2.0± 0.7 1.8± 0.4 2.3± 0.6*
Mean blood pressure (mmHg 65± 14 72± 12 61± 13 76± 12*
PCWP (mmHg) 26± 7 22± 7 19± 4 15± 4*
Lactate (mmol/l) 6.0± 4.6 4.8± 3.5 4.9± 2.3 2.9± 1.1*
Performance of Serum BNP for HF Diagnosis
BNP 
Cutoff
Sensitivit
y
Specificit
y
Positive Predictive 
Value
Negative Predictive 
Value
100 94 44 79 77
150 91 56 82 73
200 87 71 87 71
250 82 76 88 66
